Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > AME Study will be updated this Month

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Oct 08, 2021 9:55am

264 Views

Post# 33988079

RE:AME Study will be updated this Month

nozzpack wrote: $66 million in cash at June 30.
Cash burn for most recent quarter was $4,5 million.

So better than $60 million in cash when Q2 reports in early November.

Plus a Pharma with annual sales of $10 + million per year, easily worth 5 times sales with no debt..

I think 5x works in some industries but I have a feeling it doesn't work for distribution companies like Citagenix. Just going based on past Q&A with the company.

In the bigger scheme of things ... the potential for partnering on OTENA makes any CITA deal seem insignificant ... no matter what sales multiple we use.

Just a few thoughts to add.

<< Previous

Bullboard Posts

Next >>

Mullen Group: Navigates market challenges towards success